Avadel Pharmaceuticals (AVDL) EBT Margin (2016 - 2020)
Historic EBT Margin for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q2 2020 value amounting to 358.4%.
- Avadel Pharmaceuticals' EBT Margin rose 3972700.0% to 358.4% in Q2 2020 from the same period last year, while for Mar 2021 it was 17.92%, marking a year-over-year increase of 1245200.0%. This contributed to the annual value of 82.52% for FY2020, which is 549200.0% up from last year.
- According to the latest figures from Q2 2020, Avadel Pharmaceuticals' EBT Margin is 358.4%, which was up 3972700.0% from 84.74% recorded in Q1 2020.
- Over the past 5 years, Avadel Pharmaceuticals' EBT Margin peaked at 358.4% during Q2 2020, and registered a low of 496.03% during Q4 2019.
- Over the past 5 years, Avadel Pharmaceuticals' median EBT Margin value was 35.53% (recorded in 2016), while the average stood at 41.46%.
- As far as peak fluctuations go, Avadel Pharmaceuticals' EBT Margin crashed by -110565400bps in 2016, and later skyrocketed by 3972700bps in 2020.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' EBT Margin stood at 41.96% in 2016, then tumbled by -139bps to 16.36% in 2017, then crashed by -2190bps to 374.72% in 2018, then crashed by -32bps to 496.03% in 2019, then skyrocketed by 172bps to 358.4% in 2020.
- Its last three reported values are 358.4% in Q2 2020, 84.74% for Q1 2020, and 496.03% during Q4 2019.